What Vesifact does

Vesifact AG is a privately held Swiss research and development organization founded in 1987 and headquartered in Baar, Switzerland. The company develops proprietary drug delivery system technologies, with its core platform being VESIsorb® — a patented self-emulsifying drug delivery system (SEDDS) that dramatically improves the oral and topical bioavailability of poorly absorbed ingredients such as cannabinoids, CoQ10, Omega-3, terpenes, vitamins, and select pharmaceuticals. Across 33+ years, VESIsorb® has been applied to more than 50 science-backed ingredients, supported by peer-reviewed human pharmacokinetic studies demonstrating outcomes such as a 26-fold improvement in Omega-3 EPA bioavailability, a 622% increase in CoQ10 bioavailability versus oil-based formulations, and a reduction in Ibuprofen Tmax from 90 to 35 minutes.

Vesifact serves four primary vertical segments — Nutritionals, Pharmaceuticals, Cosmetics, and Medical Devices — plus an emerging Cannabis Industry vertical. The company monetizes through technology licensing royalties and bespoke B2B formulation development services, targeting enterprise customers described generically as "leading brands." It does not sell directly; instead, it relies on exclusive worldwide distribution partnerships with SourceOne Global Partners (since 2005, covering nutraceutical and general applications) and Geocann (since 2018, a joint venture covering cannabis applications). Pricing is not publicly disclosed and operates as a quote-based enterprise licensing model.

The company is founder-controlled, with CEO Marc A. Weder and co-founder Prof. Dr. H.G. Weder leading a small team (1–10 employees) that has been built around long-tenured scientists, researchers, and product developers. Vesifact has no disclosed external institutional investment, no public listing, and no disclosed revenue or funding history. Its competitive positioning rests on patented formulation technology, an extensive published clinical evidence base, and exclusive distribution agreements rather than on AI/ML capabilities or scale-driven economics.

Name

Vesifact

Legal name

Vesifact AG

Website

https://vesifact.ch

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

1–10 employees

Short description

Vesifact AG is a Swiss R&D company (founded 1987, Baar) that develops the patented VESIsorb® self-emulsifying drug delivery platform to enhance bioavailability of poorly absorbed ingredients. It licenses this technology to enterprise customers across nutritionals, pharmaceuticals, cosmetics, medical devices, and cannabis via exclusive partners SourceOne and Geocann.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology / Bioavailability Enhancement

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Surface Active Agent Manufacturing (325613)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Emulsifiers & Stabilizer Systems (Lecithin, Mono/Diglycerides, Blends) (CRADAOAE)

akta.pro secondary industries

Healthy Aging & Cognitive Support Supplements (CRADAGAM), Functional Foods & Supplement Formats (Gummies, Chews, Powders, Shots) (CRADAGAI)

Keywords

• Drug delivery systems
• Bioavailability enhancement
• Self-emulsifying formulation
• Nutraceutical formulation technology
• Pharmaceutical R&D services

Headquarters

HQ city

Baar

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: Licensing of proprietary VESIsorb® formulation technology to pharmaceutical, nutritional, cosmetics, and medical device companies for product differentiation
2. B2B Formulation Development: Research and development partnerships with leading brands to create customized drug delivery solutions

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Vesifact AG researches, develops and licenses the proprietary VESIsorb® self-emulsifying drug delivery system (SEDDS), a colloidal-droplet formulation platform that dramatically improves the oral and topical bioavailability of poorly absorbed ingredients. The technology is applied to nutritional supplements (CoQ10, Omega-3, vitamins), pharmaceutical actives (Ibuprofen, Diclofenac, Omega-3 EPA), cosmetic and personal care products (Panthenol sunburn relief, NMF moisturizers, scar treatments), medical device formulations (preservative-free dry-eye sprays), and cannabinoid/terpene products, and is delivered to brand customers through global channel partners rather than direct consumer sales.

Product overview

Vesifact is a research and development organization specializing in drug delivery system technology solutions. The company's core offering is the proprietary VESIsorb® formulation technology platform, a self-emulsifying drug delivery system (SEDDS) that enhances bioavailability of poorly absorbed ingredients. Vesifact applies this technology across four product categories: Nutritionals (CoQ10, Omega-3, Ubiquinol, Polymethoxylated Flavones, vitamins, curcumin, resveratrol), Pharmaceuticals (NSAIDs like Ibuprofen and Diclofenac), Cosmetics (panthenol-based sunburn relief, skin moisturizers), and Medical Devices (dry eye sprays, scar treatment formulations, vaginal discomfort treatments). The technology is distributed globally through exclusive partnerships with SourceOne Global Partners for nutraceutical applications and Geocann for cannabis applications.

Differentiator

Problem solved

Functional benefit

Brands

• VESIsorb: Proprietary self-emulsifying drug delivery system (SEDDS) formulation technology developed by Vesifact for enhancing bioavailability of poorly absorbed ingredients
• Dermagel

Products and services

• VESIsorb® Self-Emulsifying Drug Delivery System (SEDDS) Platform Proprietary self-emulsifying drug delivery system licensed to pharmaceutical, nutraceutical, cosmetic and medical-device companies to enhance the oral bioavailability of poorly absorbed actives such as CoQ10, Omega-3, vitamins, cannabinoids and NSAIDs, with documented improvements of up to 26-fold in AUC and Tmax reductions from 90 to 35 minutes for Ibuprofen.
• VESIsorb® Colloidal Droplet Topical Delivery System (Diclofenac / Eyelid Spray / CBD) Aqueous colloidal droplet formulation technology for topical pharmaceutical, ophthalmic and cannabis products, providing superior permeation and penetration versus marketed comparators such as Voltaren and Pennsaid for Diclofenac and preservative-free delivery for dry-eye relief sprays.
• VESIsorb® Fast-Breaking Foam Spray (Panthenol Sunburn Relief) Proprietary foam spray formulation based on the VESIsorb® colloidal droplet system, developed for Panthenol-based sunburn relief with clinically demonstrated faster onset of action, reduced redness, improved moisturizing and cooling effects versus leading market comparators.
• VESIsorb® Liposomal NMF Skin Moisturizer Liposomal Natural Moisturizing Factor formulation containing a triple amino acids complex that provides sustained, dose-dependent skin moisturization by enriching the skin's NMF rather than relying on surface humectants, targeting cosmetic brands addressing age-related NMF decline.
• VESIsorb® Dermagel® Cannabis Topical Formulation Proprietary Dermagel® topical delivery system based on VESIsorb® SEDDS, designed for cannabinoid and terpene-containing cosmetic and wellness products that require enhanced skin penetration and product differentiation.
• B2B Custom Formulation Development Services Professional R&D and formulation development service where Vesifact's team of scientists, researchers and product developers collaborates with brand customers to design and validate customized SEDDS, colloidal droplet, liposomal, foam spray and Dermagel® formulations based on their target active ingredients and application requirements.

Quantifiable outcome

• 26-fold improvement in bioavailability (AUC) for VESIsorb® Omega-3 EPA vs Rx brand in fasted state
• +6 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• GeocanncoreChannel Partner/ Reseller/ Distributor · 1 January 2018Joint venture launched in 2018 between Vesifact and SourceOne Global Partners to manage global distribution and marketing specifically for cannabis applications. Based in Fort Collins, CO USA.
• SourceOne Global PartnerscoreChannel Partner/ Reseller/ Distributor · 1 January 2005Strategic alliance formed in 2005 with vision to bring new levels of bio-enhanced formulas to the natural products industry. SourceOne, a leading provider of health and wellness solutions based in Chicago, IL USA, serves as the exclusive worldwide distribution and marketing partner for Vesifact technologies trademarked VESIsorb®.

Scale indicators9 records

Recent moves4 records

Expansion highlights5 records

Emerging players

• Bioavailability Life Sciences (BLS): Specialty bioavailability-focused company offering SEDDS and lipid-based delivery technologies for nutraceuticals and pharmaceuticals — emerging competitor with a narrower portfolio but directly comparable platform technology.
• CannaNano Therapeutics: Emerging cannabinoid delivery technology company focused on improving bioavailability of cannabis-derived actives — overlaps directly with Vesifact's Geocann-targeted cannabis applications.

Direct peers

• Camurus: Swedish drug delivery company developing novel lipid-based and FluidCrystal® formulations to improve solubility and bioavailability of poorly absorbed pharmaceuticals, addressing the same bioavailability problem Vesifact targets.
• Lipocine: US specialty pharma focused on oral delivery technologies for poorly soluble drugs, with multiple lipid/SEDDS-style platform products — directly comparable in mission and customer base (pharma partners seeking bioavailability solutions).
• ABITEC (Associated British Foods – ABF Ingredients): Manufacturer of specialty lipids, surfactants, and self-emulsifying excipients (e.g., Capmul®, Accionez®) used as functional excipients in SEDDS-style oral and topical formulations, comparable to VESIsorb® excipient platforms.
• Gattefossé: French specialty lipid and excipient manufacturer with deep expertise in SEDDS and lipid-based formulation systems used to enhance bioavailability of poorly soluble APIs and nutraceuticals — directly comparable to Vesifact's VESIsorb® SEDDS platform.

Broad incumbents

• Evonik Industries: Specialty chemicals/CDMO with pharma-grade lipid excipients and drug delivery offerings addressing solubility and bioavailability — comparable in technology overlap, though Evonik operates at significantly greater scale across multiple industries.
• Aenova Group: European pharmaceutical CDMO with formulation and drug delivery capabilities including lipid-based systems for poorly soluble compounds — serves similar pharma and nutraceutical customers with overlapping technology.
• Catalent: Large global CDMO offering formulation and drug delivery solutions including softgel and lipid-based technologies for poorly soluble APIs — overlaps with VESIsorb® in target customers and problem solved, but as part of a much broader services portfolio.
• Lonza Group: Swiss-headquartered CDMO with extensive bioavailability-enhancing formulation capabilities including lipid-based and capsule-based delivery — relevant as a large, well-capitalized competitor and potential partner for Vesifact-style SEDDS technologies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=lcg9UONMGvM
• LinkedInlinkedin.com/company/vesifact-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesifact